ARTICLE | Product Development
Alliance advancing unbranded hyperimmune globulin product for COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 30, 2020 8:31 PM UTC
The CoVIg-19 Plasma Alliance, a coalition of six plasma companies, will soon start manufacturing polyclonal hyperimmune globulin derived from recovered COVID-19 patients and could launch clinical trials in the U.S. and Europe this summer, representatives of Takeda and CSL said Thursday.
CoVIg-19 will begin manufacturing an unbranded hyperimmune globulin product “in the coming weeks” Julie Kim, president of the Plasma-Derived Therapies Business Unit at Takeda Pharmaceutical Co. Ltd. (JASDAQ:4502; NYSE:TAK), said at a briefing organized by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). ...